Evidence map›Paper›PMID 37363921›Full record

ArticlePloS one2023

The epidemiology of HIV population viral load in twelve sub-Saharan African countries.

Wolfgang Hladik, Paul Stupp, Stephen D McCracken, Jessica Justman, Clement Ndongmo, Judith Shang, Emily K Dokubo, Elizabeth Gummerson, Isabelle Koui, Stephane Bodika and 41 more

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

51 authors.

Wolfgang HladikDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.ORCID 0000-0002-3869-1711
Paul StuppDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Stephen D McCrackenDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.ORCID 0000-0002-9180-0366
Jessica JustmanICAP at Columbia University, New York, New York, United States of America.ORCID 0000-0003-4704-3115
Clement NdongmoDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.ORCID 0000-0003-0177-8458
Judith ShangDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Emily K DokuboDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.ORCID 0000-0002-1499-0151
Elizabeth GummersonICAP at Columbia University, New York, New York, United States of America.
Isabelle KouiMinistry of Health, Abidjan, Cote d'Ivoire.
Stephane BodikaDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.ORCID 0000-0002-4294-5518
Roger LobognonDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Hermann BrouICAP at Columbia University, New York, New York, United States of America.
Caroline RyanDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Kristin BrownDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.ORCID 0000-0001-9256-533X
Harriet Nuwagaba-BiribonwohaICAP at Columbia University, New York, New York, United States of America.
Leonard KingwaraNational AIDS and STI's Control Programme, Ministry of Health, Nairobi, Kenya.
Peter YoungDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.ORCID 0000-0002-7432-2876
Megan BronsonDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Duncan ChegeICAP at Columbia University, New York, New York, United States of America.
Optatus MalewoDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Yohannes MengistuDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Frederix KoenICAP at Columbia University, New York, New York, United States of America.
Andreas JahnMinistry of Health, Lilongwe, Malawi.
Andrew AuldDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.ORCID 0000-0001-5089-9163
Sasi JonnalagaddaDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Elizabeth RadinICAP at Columbia University, New York, New York, United States of America.
Ndapewa HamunimeMinistry of Health, Windhoek, Namibia.
Daniel B WilliamsDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.ORCID 0000-0003-1609-5748
Eugenie KayirangwaDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Veronicah MugishaICAP at Columbia University, New York, New York, United States of America.
Rennatus MdodoDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Stephen DelgadoICAP at Columbia University, New York, New York, United States of America.
Wilford KirungiMinistry of Health, Kampala, Uganda.
Lisa NelsonDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Christine WestDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Samuel BiraroICAP at Columbia University, New York, New York, United States of America.
Kumbutso DzekedzekeICAP at Columbia University, New York, New York, United States of America.
Danielle BarradasDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Owen MugurungiMinistry of Health and Child Care, Harare, Zimbabwe.
Shirish BalachandraDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Peter H KilmarxDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.ORCID 0000-0001-6464-3345
Godfrey MusukaICAP at Columbia University, New York, New York, United States of America.
Hetal PatelDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Bharat ParekhDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.ORCID 0000-0002-1088-4263
Katrina SleemanDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
Robert A DomaoalDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.ORCID 0000-0002-0629-9459
George RutherfordUniversity of California San Francisco, San Francisco, California, United States of America.ORCID 0000-0002-0707-8287
Tsietso MotsoaneMinistry of Health, Maseru, Lesotho.
Anne-Cécile Zoung-Kanyi BissekDivision of Operational Research for Health, Ministry of Health, Yaoundé, Cameroon.
Mansoor FarahaniICAP at Columbia University, New York, New York, United States of America.
Andrew C VoetschDivision of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.ORCID 0000-0002-0783-1312

Funding

CGH CDC HHS U2G GH001226CGH CDC HHS U2G GH001271PEPFAR
6 · The paper itself

Abstract

backgroundWe examined the epidemiology and transmission potential of HIV population viral load (VL) in 12 sub-Saharan African countries.

methodsWe analyzed data from Population-based HIV Impact Assessments (PHIAs), large national household-based surveys conducted between 2015 and 2019 in Cameroon, Cote d'Ivoire, Eswatini, Kenya, Lesotho, Malawi, Namibia, Rwanda, Tanzania, Uganda, Zambia, and Zimbabwe. Blood-based biomarkers included HIV serology, recency of HIV infection, and VL. We estimated the number of people living with HIV (PLHIV) with suppressed viral load (<1,000 HIV-1 RNA copies/mL) and with unsuppressed viral load (viremic), the prevalence of unsuppressed HIV (population viremia), sex-specific HIV transmission ratios (number female incident HIV-1 infections/number unsuppressed male PLHIV per 100 persons-years [PY] and vice versa) and examined correlations between a variety of VL metrics and incident HIV. Country sample sizes ranged from 10,016 (Eswatini) to 30,637 (Rwanda); estimates were weighted and restricted to participants 15 years and older.

resultsThe proportion of female PLHIV with viral suppression was higher than that among males in all countries, however, the number of unsuppressed females outnumbered that of unsuppressed males in all countries due to higher overall female HIV prevalence, with ratios ranging from 1.08 to 2.10 (median: 1.43). The spatial distribution of HIV seroprevalence, viremia prevalence, and number of unsuppressed adults often differed substantially within the same countries. The 1% and 5% of PLHIV with the highest VL on average accounted for 34% and 66%, respectively, of countries' total VL. HIV transmission ratios varied widely across countries and were higher for male-to-female (range: 2.3-28.3/100 PY) than for female-to-male transmission (range: 1.5-10.6/100 PY). In all countries mean log10 VL among unsuppressed males was higher than that among females. Correlations between VL measures and incident HIV varied, were weaker for VL metrics among females compared to males and were strongest for the number of unsuppressed PLHIV per 100 HIV-negative adults (R2 = 0.92).

conclusionsDespite higher proportions of viral suppression, female unsuppressed PLHIV outnumbered males in all countries examined. Unsuppressed male PLHIV have consistently higher VL and a higher risk of transmitting HIV than females. Just 5% of PLHIV account for almost two-thirds of countries' total VL. Population-level VL metrics help monitor the epidemic and highlight key programmatic gaps in these African countries.

Indexed as

Anti-HIV AgentsHIV InfectionsAdultFemaleHumansLesothoMaleSeroepidemiologic StudiesViral LoadViremiaZimbabweAnti-HIV Agents

Identifiers

PMID37363921
PMCPMC10292693

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.